Chilblain-like lesion associated with coronavirus disease 2019 vaccine in tropical country: a case report.

IF 0.9 Q3 MEDICINE, GENERAL & INTERNAL

Journal of Medical Case Reports Pub Date : 2025-05-07 DOI:10.1186/s13256-025-05254-7

Wasuchon Chaichan, Mati Chuamanochan, Pongsak Mahanupab, Siri Chiewchanvit, Napatra Tovanabutra

{"title":"Chilblain-like lesion associated with coronavirus disease 2019 vaccine in tropical country: a case report.","authors":"Wasuchon Chaichan, Mati Chuamanochan, Pongsak Mahanupab, Siri Chiewchanvit, Napatra Tovanabutra","doi":"10.1186/s13256-025-05254-7","DOIUrl":null,"url":null,"abstract":"Background: Chilblains have emerged as a cutaneous manifestation following coronavirus disease 2019 vaccination. While there are many case reports on chilblain-like lesions, documentation from tropical countries remains limited. In this context, we report a case detailing chilblain-like lesions associated with coronavirus disease 2019 vaccination in Thailand.Case presentation: A 35-year-old Thai female patient presented with several painful, red papules on the fingers and toes 9 days after receiving the mRNA-1273 vaccination. Skin biopsy was performed, and the results were consistent with chilblains. Laboratory workup revealed positive result for lupus anticoagulant. The rash completely resolved without any treatment but reappeared following the second vaccine dose.Conclusion: Chilblain-like lesion following coronavirus disease 2019 vaccination is frequently observed in temperate countries, with few reports from tropical areas. The presence of lupus anticoagulant may contribute to the development of chilblains after coronavirus disease 2019 vaccination.","PeriodicalId":16236,"journal":{"name":"Journal of Medical Case Reports","volume":"19 1","pages":"213"},"PeriodicalIF":0.9000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057029/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13256-025-05254-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chilblains have emerged as a cutaneous manifestation following coronavirus disease 2019 vaccination. While there are many case reports on chilblain-like lesions, documentation from tropical countries remains limited. In this context, we report a case detailing chilblain-like lesions associated with coronavirus disease 2019 vaccination in Thailand.

Case presentation: A 35-year-old Thai female patient presented with several painful, red papules on the fingers and toes 9 days after receiving the mRNA-1273 vaccination. Skin biopsy was performed, and the results were consistent with chilblains. Laboratory workup revealed positive result for lupus anticoagulant. The rash completely resolved without any treatment but reappeared following the second vaccine dose.

Conclusion: Chilblain-like lesion following coronavirus disease 2019 vaccination is frequently observed in temperate countries, with few reports from tropical areas. The presence of lupus anticoagulant may contribute to the development of chilblains after coronavirus disease 2019 vaccination.

查看原文本刊更多论文

热带国家2019冠状病毒病疫苗相关冻疮样病变1例报告

背景：冻疮是2019冠状病毒病疫苗接种后出现的一种皮肤表现。虽然有许多关于冻疮样病变的病例报告，但来自热带国家的文献仍然有限。在此背景下，我们报告了一个病例，详细介绍了泰国2019冠状病毒病疫苗接种相关的冻疮样病变。病例介绍：一名35岁的泰国女性患者在接种mRNA-1273疫苗9天后出现手指和脚趾上的几个疼痛的红色丘疹。进行了皮肤活检，结果与冻疮一致。实验室检查显示狼疮抗凝血剂阳性。皮疹在没有任何治疗的情况下完全消失，但在第二次接种疫苗后再次出现。结论：2019冠状病毒病疫苗接种后冻疮样病变常见于温带国家，热带地区报告较少。狼疮抗凝剂的存在可能导致2019冠状病毒病疫苗接种后冻疮的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Case Reports Medicine-Medicine (all)

CiteScore

1.50

自引率

0.00%

发文量

436

期刊介绍： JMCR is an open access, peer-reviewed online journal that will consider any original case report that expands the field of general medical knowledge. Reports should show one of the following: 1. Unreported or unusual side effects or adverse interactions involving medications 2. Unexpected or unusual presentations of a disease 3. New associations or variations in disease processes 4. Presentations, diagnoses and/or management of new and emerging diseases 5. An unexpected association between diseases or symptoms 6. An unexpected event in the course of observing or treating a patient 7. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect